{
    "clinical_study": {
        "@rank": "109248", 
        "acronym": "NATRUL-4", 
        "arm_group": [
            {
                "arm_group_label": "HMPL-004 1800 mg/day", 
                "arm_group_type": "Experimental", 
                "description": "HMPL-004 600 mg tablet given t.i.d."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "600 mg Placebo tablet given t.i.d."
            }
        ], 
        "brief_summary": {
            "textblock": "A study with an 8 week open label phase study followed by a year long placebo controlled\n      maintenance phase in subjects with active mild to moderate ulcerative colitis (UC), with a\n      modified Mayo Score 4-10 and an endoscopy subscore of 2-3, taking mesalamine (or equivalent)\n      as a concomitant medication. Subjects are required to be in clinical remission or clinical\n      response to enter the year long maintenance phase.  This study will help evaluate if\n      HMPL-004 is effective in subjects maintaining clinical remission following successful\n      induction therapy achieving clinical remission or clinical response."
        }, 
        "brief_title": "A Phase III Maintenance Placebo Controlled Maintenance Trial Of HMPL-004 in Subjects With Mild to Moderate Ulcerative Colitis", 
        "condition": "Ulcerative Colitis", 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Ulcer"
            ]
        }, 
        "detailed_description": {
            "textblock": "A two-phase multi-center study with an open label 8-week induction phase and a randomized,\n      double-blind, placebo controlled maintenance phase to evaluate the efficacy and safety of\n      HMPL-004 for a 52-week maintenance therapy in adults with mild to moderate UC and who have\n      demonstrated a sub-optimal response to mesalamine treatment. The study participants will\n      consist of subjects who have completed either the HMPL-004-03 or HMPL-004-05 induction\n      study, complemented by the enrollment of additional subjects in the open label induction\n      phase who meet the entry criteria of this study. . Subjects entering this maintenance study\n      from one of the HMPL-004 induction studies will have their modified Mayo baseline score from\n      that study as their baseline score for this study. All subjects enrolled in the open label\n      induction phase of the study will be re-evaluated for clinical response and remission after\n      the 8-week open label 2400 mg HMPL-004 treatment period. Clinical responders and remitters\n      will be randomized 2:1 (HMPL-004: placebo) to HMPL-004 1800 mg/day or placebo group for the\n      52-week maintenance phase of the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Completion of induction study HMPL-004-03 or HMPL-004-05 and achieving clinical\n             remission or response with no disruption of study treatment in the transition to\n             HMPL-004-04, or, for the open label induction phase of the study: have active mild to\n             moderate Ulcerative Colitis defined by a modified Mayo Score of 4 to 10 and with\n             endoscopy score activity of 2-3 points confirmed by a full colonoscopy within 2 weeks\n             prior to study.\n\n          2. Subjects must be currently receiving mesalamine \u2265 2.4 g/day (or the equivalent) for\n             at least 6 weeks prior to randomization and on a stable dosage for at least 2 weeks\n             prior to entering the screening phase of the study to ensure a stable dose is\n             established at least 2 weeks prior to the endoscopic procedures.\n\n          3. Have adequate renal, hepatic and bone marrow function (see exclusion criteria).\n\n          4. Age \u2265 18 years\n\n          5. All fertile male and female subjects must agree to use one of the following types of\n             contraception: intrauterine device, implantable progesterone device, progesterone\n             intramuscular injection, oral contraceptive which has been started at least one month\n             prior to visit one and continues for the duration of the trial, contraceptive patch,\n             or condom with spermicide.\n\n          6. Show evidence of a personally signed and dated informed consent document indicating\n             that the subject (or legally acceptable representative) has been informed of all\n             pertinent aspects of the trial.\n\n        Exclusion Criteria:\n\n          1. Subjects with intolerance to mesalamine (or equivalent medications).\n\n          2. Diagnosed with Crohn's disease or with lesions such as fistulas or granulomas on\n             biopsy noted either in history or at baseline endoscope, which would be suspicious\n             for Crohn's disease, or with a diagnosis of indeterminate colitis.\n\n          3. Severe disease with a Ulcerative Colitis modified Mayo Clinic score above 10 points\n             at baseline.\n\n          4. Positive stool test for pathogens on sample taken within the 2 weeks prior to study\n             entry.\n\n          5. Active clostridium difficile (C. diff) infection.\n\n          6. Use of Inflammatory Bowel Disease related herbal supplements including supplements\n             containing andrographis or the use of probiotics two weeks prior to study entry or\n             during the study.\n\n          7. Toxic megacolon or toxic colitis.\n\n          8. Probable requirement for intestinal surgery within 12 weeks after the start of\n             investigational product.\n\n          9. Receiving oral or rectal steroids within 1 month prior to study entry.\n\n         10. Receiving rectal mesalamine within 1 week prior to study entry.\n\n         11. Receiving azathioprine, 6-mercaptopurine, methotrexate, tacrolimus, cyclosporine, or\n             other immunosuppressive therapy at the time of screening or within the preceding 6\n             weeks.\n\n         12. Receiving anti-TNF-\u03b1 agents such as infliximab, adalimumab, golimumab, or\n             certolizumab pegol at the time of screening or within the preceding 8 weeks.\n\n         13. Receiving other investigational drugs or biologics within 1 month or five half-lives,\n             whichever is longer.\n\n         14. Receiving antibiotics within 2 weeks of study entry.\n\n         15. Hemoglobin concentration <9 g/dl.\n\n         16. WBC below 3,000/cm3, or platelets below 100,000/cm3.\n\n         17. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and/or alkaline\n             phosphatase >2.5 upper limit of normal.\n\n         18. Serum creatinine >1.5 times upper limit of normal.\n\n         19. Significant concurrent medical diseases including: active peptic ulcer disease;\n             uncompensated congestive heart disease; myocardial infarction within the last 12\n             months; unstable angina pectoris; uncontrolled hypertension; and pulmonary disease\n             requiring oxygen therapy.\n\n         20. Chronic Hepatitis B or any history of Hepatitis C.\n\n         21. Previous colonic surgery except for simple polypectomy.\n\n         22. History of cancer within the last 5 years other than resected cutaneous basal and\n             squamous cell carcinomas, and/or in situ cervical cancer.\n\n         23. Subjects with a history of or concurrent colonic dysplasia associated with UC, except\n             those with completely excised sporadic colorectal polyps.\n\n         24. Women who are pregnant or breast feeding.\n\n         25. Subjects known to be seropositive for HIV, or who have had an AIDS defining illness,\n             or a known immunodeficiency disorder.\n\n         26. History of alcohol or drug abuse that would interfere with the ability to be\n             compliant with the study procedure.\n\n         27. Known allergy to plants of the Acanthaceae family.\n\n         28. Unwillingness to participate in the study.\n\n         29. Any underlying medical condition that in the Investigator's opinion will make the\n             administration of study drug hazardous to the subject or would obscure the\n             interpretation of Adverse Events."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "460", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01882764", 
            "org_study_id": "HMPL-004-04"
        }, 
        "intervention": [
            {
                "arm_group_label": "HMPL-004 1800 mg/day", 
                "description": "HMPL-004 tablet given at a strength of 1800 mg/day, (600 mg t.i.d.)", 
                "intervention_name": "HMPL-004 tablet", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo Tablet", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Agawam", 
                    "country": "United States", 
                    "state": "Massachusetts"
                }, 
                "name": "Clinical Research Management, Inc."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III Double Blind, Multi-Center Placebo Controlled Maintenance Trial of HMPL-004 in Subjects With Mild to Moderate Ulcerative Colitis With Clinical Remission or Response From Induction Therapy. (NATRUL-4)", 
        "overall_contact": {
            "email": "Gerald McPherson <GMcpherson@clinicalresearchmgt.com>", 
            "last_name": "Gerald McPherson", 
            "phone": "512 301 7615"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is the proportion of subjects who are in clinical remission after 52 weeks of maintenance treatment, following successful induction therapy to achieve clinical remission or clinical response.  Clinical remission is defined as a modified Mayo Score \u22642 along with no individual score >1 AND rectal bleeding score = 0. The Mayo Scoring system used for this study has been modified to allow mild friability to be scored as a 2 (moderate disease). Clinical response is defined as a decrease in the modified Mayo Score from baseline by \u2265 3 points AND \u2265 30% decrease in the modified Mayo Score, along with either a decrease in the rectal bleeding score \u2265 1 OR an absolute rectal bleeding score \u2264 1.", 
            "measure": "The Efficacy of HMPL-004 in the maintenance of clinical remission", 
            "safety_issue": "No", 
            "time_frame": "After 1 year of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01882764"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Hutchison Medipharma Limited", 
        "sponsors": {
            "collaborator": {
                "agency": "Nutrition Science Partners Limited", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Hutchison Medipharma Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}